# US 2012/0252787 A1 · Administration of an anti-obesity compound to individuals with renal impairment

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252787 A1
- Document ID: US20120252787A1
- Status: Published application
- Kind: A1
- Application number: 13/511,639
- Filed: 2011-08-31
- Published: 2012-10-04
- Earliest claimed: 2010-09-01
- Assignees: Arena Pharmaceuticals, Inc.
- Inventors: Christen M. Anderson; William R. Shanahan
- Web page: https://patentgrep.com/patent/US20120252787A1

## CPC

- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 13/12: of the kidneys
- G01N 33/70: involving creatine or creatinine
- Y10T 436/147777: Plural nitrogen in the same ring [e.g., barbituates, creatinine, etc.]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The present disclosure relates to methods for weight management in an individual in need thereof by determining the level of renal sufficiency of the individual and prescribing or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual, provided that the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment. In addition, the disclosure relates to a method for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management by determining the level of renal sufficiency of the individual and selecting the individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof if the individual has a level of renal sufficiency selected from the group consisting of: no renal impairment, mild renal impairment, and moderate renal impairment.

## Claims

### Claim at position 1

-40. (canceled)

### Claim 41

A method for weight management, for decreasing food intake, for inducing satiety, for treating obesity, and/or for preventing obesity in an individual in need thereof, comprising:
prescribing and/or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual,
provided that the individual does not have severe renal impairment or end stage renal disease.

### Claim 42 (depends on 41)

The method of claim 41, further comprising prescribing or administering a reduced-calorie diet.

### Claim 43 (depends on 41)

The method of claim 41, further comprising prescribing or administering a program of regular exercise.

### Claim 44 (depends on 41)

The method of claim 41, further comprising prescribing or administering phentermine to the individual.

### Claim 45 (depends on 41)

The method of claim 41, wherein the Cockcroft-Gault equation is used to determine the level of renal sufficiency of the individual.

### Claim 46 (depends on 45)

The method of claim 45, wherein the individual has a creatinine clearance rate of greater than about 30 mL/minute using the Cockcroft-Gault equation.

### Claim 47 (depends on 41)

The method of claim 41, wherein the individual's serum creatinine concentration is used to determine the level of renal sufficiency of the individual.

### Claim 48 (depends on 47)

The method of claim 47, wherein the individual has an approximate serum creatinine concentration of:
(i) less than 4.9 mg/dL for an 18-20 year old man,
(ii) less than 3.5 mg/dL for an 18-20 year old woman,
(iii) less than 4.5 mg/dL for a 21-30 year old man,
(iv) less than 3.2 mg/dL for a 21-30 year old woman,
(v) less than 4.1 mg/dL for a 31-40 year old man,
(vi) less than 2.9 mg/dL for a 31-40 year old woman,
(viii) less than 2.7 mg/dL for a 41-50 year old woman,
(ix) less than 3.3 mg/dL for a 51-60 year old man,
(x) less than 2.4 mg/dL for a 51-60 year old woman,
(xi) less than 3.0 mg/dL for a man over 60 years old, or
(xii) less than 2.0 mg/dL for a woman over 60 years old.

### Claim 49 (depends on 41)

The method of claim 41, wherein the individual has mild renal impairment.

### Claim 50 (depends on 41)

The method of claim 41, wherein the individual has moderate renal impairment.

### Claim 51 (depends on 41)

The method of claim 41, wherein said administering results in a reduction in the risk of an adverse event.

### Claim 52 (depends on 41)

The method of claim 41, wherein weight management comprises weight loss.

### Claim 53 (depends on 41)

The method of claim 41, wherein weight management comprises maintenance of weight loss.

### Claim 54 (depends on 41)

The method of claim 41, wherein the individual is an individual with an initial body mass index ≧25 kg/m2.

### Claim 55 (depends on 54)

The method of claim 54, wherein the individual has at least one weight related comorbid condition.

### Claim 56 (depends on 55)

The method of claim 55, wherein the weight related comorbid condition is selected from the group consisting of: hypertension, dyslipidemia, cardiovascular disease, glucose intolerance and sleep apnea.

### Claim 57 (depends on 41)

The method of claim 41, wherein the individual is an individual with an initial body mass index ≧27 kg/m2.

### Claim 58 (depends on 57)

The method of claim 57, wherein the individual has at least one weight related comorbid condition.

### Claim 59 (depends on 58)

The method of claim 58, wherein the weight related comorbid condition is selected from the group consisting of: hypertension, dyslipidemia, cardiovascular disease, glucose intolerance and sleep apnea.

### Claim 60 (depends on 41)

The method of claim 41, wherein the individual is an individual with an initial body mass index ≧30 kg/m2.

### Claim 61 (depends on 41)

The method of claim 41, wherein the compound is selected from: (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride and pharmaceutically acceptable solvates and hydrates thereof.

### Claim 62 (depends on 41)

The method of claim 41, wherein the compound is (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrochloride salt hemihydrate.

### Claim 63

A method for weight management, for decreasing food intake, for inducing satiety, for treating obesity, and/or for preventing obesity in an individual in need thereof, comprising:
prescribing and/or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual,
provided that the individual is selected from the group of individuals having no renal impairment, mild renal impairment, and moderate renal impairment.

### Claim 64

A method for weight management, for decreasing food intake, for inducing satiety, for treating obesity, and/or for preventing obesity in an individual in need thereof, comprising:
prescribing and/or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual,
provided that the individual has mild renal impairment or moderate renal impairment.

### Claim 65

A method for weight management, for decreasing food intake, for inducing satiety, for treating obesity, and/or for preventing obesity in an individual in need thereof, comprising:
determining the renal sufficiency level of the individual, and
prescribing and/or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual,
provided that the individual does not have severe renal impairment or end stage renal disease.

### Claim 66

A method for weight management, for decreasing food intake, for inducing satiety, for treating obesity, and/or for preventing obesity in an individual in need thereof, comprising:
determining the renal sufficiency level of the individual, and
prescribing and/or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual,
provided that the individual is selected from the group of individuals having no renal impairment, mild renal impairment, and moderate renal impairment.

### Claim 67

A method for weight management, for decreasing food intake, for inducing satiety, for treating obesity, and/or for preventing obesity in an individual in need thereof, comprising:
determining the renal sufficiency level of the individual, and
prescribing and/or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual,
provided that the individual has mild renal impairment or moderate renal impairment.

### Claim 68

A method for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof, comprising
determining the renal sufficiency level of the individual in need of treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof,
selecting an individual with a creatinine clearance rate of no less than 31 mL/minute, and
prescribing and/or administering a therapeutically effective amount of (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof to the individual.

### Claim 69

A kit for weight management, decreasing food intake, inducing satiety, treating obesity, and/or preventing obesity in an individual in need thereof, comprising:
a) a therapeutically effective amount of R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof, and
b) instructions indicating that the compound is to be administered to the individual provided that the individual does not have severe renal impairment or end stage renal disease

### Claim 70 (depends on 69)

The kit of claim 69, further comprising phentermine.
